Skip to main content
FARON PHARMACEUTICALS OY logo

FARON PHARMACEUTICALS OY — Investor Relations & Filings

Ticker · FARN ISIN · FI4000153309 LEI · 7437009H31TO1DC0EB42 IL Manufacturing
Open in API
Filings indexed 626 across all filing types
Latest filing 2025-06-05 Director's Dealing
Country FI Finland
Listing IL FARN

About FARON PHARMACEUTICALS OY

https://faron.com/

Faron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer. The company pioneers macrophage-targeting therapies to leverage the patient's immune system, aiming to address unmet medical needs and improve outcomes. Its lead asset, bexmarilimab, is a first-in-class anti-Clever-1 antibody and a myeloid cell-targeting immunotherapy candidate. Bexmarilimab is being investigated in clinical trials as a potential therapy for hematological malignancies and solid tumors, often in combination with standard-of-care treatments.

Recent filings

Filing Released Lang Actions
Faron Pharmaceuticals Ltd: Director/PCA Dealing and Donation of Shares to Foundation
Director's Dealing Classification · 100% confidence The document explicitly announces transactions involving shares by a director (Markku Jalkanen) and a person closely associated (Sirpa Jalkanen), including donations and sales. The title is "Faron Pharmaceuticals Ltd: Director/PCA Dealing and Donation of Shares to Foundation". This directly corresponds to the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The presence of the 'Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014' further confirms this is an insider transaction disclosure.
2025-06-05 English
Faron Pharmaceuticals Ltd: Registration of New Shares
Share Issue/Capital Change Classification · 98% confidence The document is a company announcement from Faron Pharmaceuticals Ltd dated June 3, 2025, titled "Registration of New Shares." The text explicitly details the registration of 5,352,989 new shares following the exercise of Special Rights and mentions the resulting total number of shares and voting rights. This content directly relates to changes in the company's capital structure (issuance of new shares). This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). Although it is a regulatory news distribution service (MFN) announcement, the core subject matter is a capital change, making SHA the most specific and accurate classification over the general RNS fallback.
2025-06-03 English
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds
Capital/Financing Update Classification · 98% confidence The document announces the approval of share subscriptions related to the amortization of convertible bonds, resulting in the issuance of new shares and a change in the total number of voting rights. This directly concerns the company's capital structure and financing arrangements, specifically the conversion of debt into equity via special rights. This aligns best with the 'Capital/Financing Update' category (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it details a specific financing mechanism outcome.
2025-06-03 English
Faron Pharmaceuticals presents Phase II data from BEXMAB Study at ASCO 2025
Regulatory Filings Classification · 95% confidence The document is a press release dated June 02, 2025, announcing the presentation of Phase II clinical trial data (BEXMAB study results for bexmarilimab) at the ASCO 2025 Annual Meeting. It contains key efficacy and survival data, quotes from management and investigators, and details about the presentation. This format—a formal announcement of clinical trial results and upcoming presentations/webinars—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a detailed announcement of clinical progress and data presentation, and not a full financial report (10-K, IR) or a transcript (CT), it fits best as an Earnings Release (ER) which often includes operational/clinical highlights, or RNS as a general regulatory announcement. Given the focus on presenting new data and the structure of a press release, ER is a strong candidate, but RNS is the most appropriate fallback for non-standard regulatory/operational news distribution. However, since it is a detailed announcement of clinical trial results, which often accompanies or precedes formal earnings, and it is not explicitly an earnings report, I will classify it as a general Regulatory Filing (RNS) as it is distributed via a Regulatory News Service (MFN) and details operational/clinical progress rather than core financial performance metrics typical of an ER.
2025-06-02 English
Faron announces publication of full Phase I BEXMAB study data in Lancet Haematology
Regulatory Filings Classification · 90% confidence The document is a press release from Faron Pharmaceuticals announcing the publication of full Phase I study data for their drug BEXMAB in the journal *Lancet Haematology*. It details clinical findings, safety profiles, and survival statistics. While it discusses clinical trial results, it is not the comprehensive Annual Report (10-K), an Interim Report (IR), or a standalone Audit Report (AR). It is a specific announcement of scientific/clinical data dissemination. Since it is a formal announcement of results and not a general regulatory filing fallback (RNS) or a presentation (IP), and it is not a transcript (CT) or a management discussion (MDA), the closest fit among the specific options is difficult. However, it is a detailed announcement of clinical/scientific progress, which often falls under Investor Presentation (IP) if it were a slide deck, or sometimes Regulatory Filing (RNS) if no better fit exists. Given the content is a detailed press release summarizing scientific data, it is most closely related to the type of information shared in an Investor Presentation (IP) or a detailed Earnings Release (ER) if it were quarterly results. Since it is specifically about the publication of study data, and not a general earnings report, and it is not a proxy statement or governance document, it functions as a key piece of investor information. Because it is a detailed announcement of clinical trial results, which is a core component of investor relations material, 'Investor Presentation' (IP) is a plausible category for detailed scientific updates, although 'Regulatory Filing' (RNS) is the general fallback. Given the high level of detail on clinical outcomes, it functions similarly to an investor update presentation. However, looking strictly at the definitions, it is a 'Press Release' announcing a publication. This type of announcement, which is not a standard financial report (10-K, IR, ER), often defaults to RNS or is sometimes categorized as IP if it contains presentation-like material. Since it is a formal press release announcing a major scientific milestone, and not a general regulatory filing, I will classify it as RNS as the most appropriate general regulatory/news announcement category when specific report types don't match, or IP if we consider it an investor update. Given the structure and purpose (disseminating key data to investors), IP is a strong candidate, but RNS is the safest catch-all for non-standard announcements. I will lean towards RNS as it is a general regulatory news distribution service announcement (MFN is mentioned at the end).
2025-05-30 English
Faron Pharmaceuticals Ltd: Issue of Treasury Shares to the Company
Share Issue/Capital Change Classification · 99% confidence The document announces the resolution by the Board of Directors to issue 5,000,000 treasury shares to the Company itself without consideration, specifically to prepare for future conversions or amortization of convertible bonds. This action directly relates to changes in the company's capital structure (issuing shares, even if held in treasury initially) and financing activities (related to convertible bonds). Reviewing the definitions, 'Capital/Financing Update (CAP)' is the most appropriate fit as it covers 'Updates on company fundraising, financing activities, or capital structure changes.' While 'Transaction in Own Shares (POS)' deals with buying back or selling shares, this announcement is about issuing shares into treasury specifically tied to a financing instrument (convertible bond), making CAP a stronger classification for the underlying corporate action context. It is not an earnings release, an annual report, or a proxy statement.
2025-05-27 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.